Wedbush Raises Kiniksa Pharmaceuticals Price Target to $102
Wedbush raised its price target on Kiniksa Pharmaceuticals to $102 from $99 and maintained an Outperform rating.
Related stories
ULA Vulcan Rocket Fails, Destroying Payload of 40 Amazon Satellites
United Launch Alliance’s Vulcan rocket failed shortly after launching from Florida on Sunday, destroying 40 satellites for Amazon’s Leo internet network.
M impact | EQUITY | Nov 15, 2026, 08:46 PM UTC
Rocket Failure Destroys Payload of Amazon Satellites
A rocket from a Boeing-Lockheed venture failed mid-flight and destroyed its payload of Amazon satellites.
M impact | EQUITY | Nov 15, 2026, 08:46 PM UTC
ULA Vulcan Rocket Fails After Launch, 40 Amazon Satellites Doomed
A United Launch Alliance Vulcan rocket failed shortly after launch, dooming 40 Amazon low-Earth-orbit internet satellites.
M impact | EQUITY | Nov 15, 2026, 08:15 PM UTC
Serko Raises Annual Revenue Guidance as Business Travel Remains Robust
Serko reported first-half revenue of NZ$72.3 million, up 17% year on year, and a net loss of NZ$870,000. It said it will not pay an interim dividend and had NZ$63 million in cash a
M impact | EQUITY | Nov 15, 2026, 08:08 PM UTC
Nebius Reports Q3 Results, Narrows 2026 Revenue Guidance
Nebius said Q3 2026 results surpassed market estimates. Shares fell 17% as management narrowed its 2026 revenue outlook, citing delays bringing data center capacity online and high
M impact | EQUITY | Nov 15, 2026, 08:02 PM UTC
Maire to Acquire Natural Gas Liquefaction Process Technologies From Chart Industries
M impact | EQUITY | Nov 15, 2026, 07:53 PM UTC